From 1 July 2025, there are new arrangements for the supply of measles-containing vaccines under the 国家免疫计划（NIP）. Whereas previously both GSK and CLS supplied these vaccines, now only GSK will supply them.
Vaccine providers cannot place new orders for CSL’s M-M-R II (MMR) or Varivax (varicella). But existing stock should still be used until it either expires or runs out.
Providers can now only order GSK’s Priorix (MMR), Priorix-Tetra (MMR) and Varilrix (varicella).